Bone turnover markers in primary hyperparathyroidism (Q27692682)

Bilezikian JP

series ordinal

2

1 reference

language of work or name

English

0 references

publication date

2013

1 reference

Journal of Clinical Densitometry

published in

1 reference

volume

16

1 reference

issue

1

1 reference

page(s)

22-7

1 reference

Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3577420

SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3577420

Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3577420

Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3577420

Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3577420

Circulating sclerostin in disorders of parathyroid gland function

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3577420

Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3577420

Alendronate therapy in men with primary hyperparathyroidism

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3577420

Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3577420

Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3577420

The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3577420

Cinacalcet for the treatment of primary hyperparathyroidism

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3577420

Primary hyperparathyroidism and the skeleton

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3577420

Remarkable increase in lumbar spine bone mineral density and amelioration in biochemical markers of bone turnover after parathyroidectomy in elderly patients with primary hyperparathyroidism: a 5-year follow-up study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3577420

Primary hyperparathyroidism: new concepts in clinical, densitometric and biochemical features

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3577420

Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3577420

The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3577420

Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3577420

Primary hyperparathyroidism: bone structure, balance, and remodeling before and 3 years after surgical treatment.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3577420

Estrogen replacement may be an alternative to parathyroid surgery for the treatment of osteoporosis in elderly postmenopausal women presenting with primary hyperparathyroidism: a preliminary report

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3577420

Primary hyperparathyroidism: changes in the pattern of clinical presentation

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3577420

Metabolic Effects of Diphosphonate in Primary Hyperparathyroidism

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3577420

Primary hyperparathyroidism: biochemical markers and bone mineral density at multiple skeletal sites in Danish patients.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3577420

Longitudinal measurements of bone density and biochemical indices in untreated primary hyperparathyroidism.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3577420

Bone structure in postmenopausal hyperparathyroid, osteoporotic, and normal women

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3577420

Potential utility of high preoperative levels of serum type I collagen markers in postmenopausal women with primary hyperparathyroidism with respect to their short-term variations after parathyroidectomy

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3577420

Acute and one-year effects of cinacalcet in patients with persistent primary hyperparathyroidism after unsuccessful parathyroidectomy

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3577420

Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schonberg disease (type II autosomal dominant osteopetrosis).

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3577420

Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3577420

Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3577420

Alendronate in the treatment of primary hyperparathyroid-related osteoporosis: a 2-year study

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3577420

Raloxifene reverses bone loss in postmenopausal women with mild asymptomatic primary hyperparathyroidism

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3577420

Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3577420

Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls

27 November 2018

1 reference

12 December 2020

Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism

1 reference

12 December 2020

Decreased serum sclerostin levels in patients with primary hyperparathyroidism: a cross-sectional and a longitudinal study

1 reference

12 December 2020

The usefulness of high pre-operative levels of serum type I collagen bone markers for the prediction of changes in bone mineral density after parathyroidectomy

1 reference

12 December 2020

Immediate changes in biochemical markers of bone turnover and circulating interleukin-6 after parathyroidectomy for primary hyperparathyroidism

1 reference

12 December 2020

Effects of hormone replacement therapy on bone mineral density in postmenopausal women with primary hyperparathyroidism: four-year follow-up and comparison with healthy postmenopausal women

1 reference

12 December 2020

Osteoprotegerin Levels in Primary Hyperparathyroidism: Effect of Parathyroidectomy and Association with Bone Metabolism

1 reference

12 December 2020

Treatment with with oestrogens of primary hyperparathyroidism in post-menopausal women

1 reference

12 December 2020

Effects of dichloromethylene diphosphonate on serum and urinary calcium in primary hyperparathyroidism

1 reference

12 December 2020

Conjugated Estrogens in the Treatment of Postmenopausal Women with Hyperparathyroidism

1 reference

12 December 2020

Ethinyl estradiol and norethindrone in the treatment of primary hyperparathyroidism in postmenopausal women

1 reference

12 December 2020

Changes in bone mass and metabolism after surgery for primary hyperparathyroidism

1 reference

12 December 2020

Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism. A randomized, controlled trial

1 reference

12 December 2020

Circulating levels of interleukin-6 and tumor necrosis factor-alpha are elevated in primary hyperparathyroidism and correlate with markers of bone resorption--a clinical research center study

1 reference

12 December 2020

Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism

1 reference

12 December 2020

Changes in bone mass and serum markers of bone metabolism after parathyroidectomy

1 reference

12 December 2020

Increased biochemical markers of bone formation and resorption in primary hyperparathyroidism with special reference to patients with mild disease

1 reference

12 December 2020

Novel Serum Markers of Bone Resorption: Clinical Assessment and Comparison with Established Urinary Indices

1 reference

12 December 2020

Primary hyperparathyroidism: short-term changes in bone remodeling and bone mineral density following parathyroidectomy

1 reference

12 December 2020